Oral GLP-1

Jul 10, 2026

Summary The obesity treatment market has shifted from a niche category to a major pharma growth engine, with revenues in the leading markets rising from about $16 billion in 2025 to a projected $80 billion by 2034 and potentially more than $100 billion by 2036. Eli Lilly led the category in 2025, driven by M...

Jun 15, 2026

Summary The obesity drug landscape is shifting from injectable GLP-1s to oral pill-based treatments, marking a major turning point in pharmacotherapy. Two oral GLP-1s have now received FDA approval: Novo Nordisk's WEGOVY pill (December 2025) and Eli Lilly's FOUNDAYO (April 2026). Several companies, such a...